Utilizing Next-Gen Sequencing and biomarker analysis, Paradigm Diagnostics offers the Paradigm Cancer Diagnostic (PCDx) test, which provides comprehensive genomic and proteomic information about a patient's cancer. This information helps oncologists tailor treatment plans to each individual patient. Paradigm Diagnostics was acquired by Exact Sciences on March 3rd, 2020, and their technology enables personalized cancer diagnostics and biomarker-driven clinical trials to benefit cancer patients.